| Overview |
| bs-0668r-cy7-100ul |
| MET Polyclonal Antibody, Cy7 Conjugated |
| WB, IF |
| Human, Mouse, Rat |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from mouse MET |
| Polyclonal |
| IgG |
| 1mg/ml |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 4233 |
| P16056 |
| Secreted, Cell membrane |
| MET_HUMAN; Hepatocyte growth factor receptor; EC:2.7.10.1; HGF receptor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factor receptor(SF receptor); Tyrosine-protein kinase Met; MET proto-oncogene, receptor tyrosine kinase; DA11; HGFR; AUTS9; RCCP2; c-Met; c Met; DFNB97; |
| This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016] |
| Application Dilution |
| WB |
=1:500-2000 |
| IF |
IF=1:100-500 |
Powered by Bioz